OCULAR THERAPEUTIX INC. news, videos and press releases
For more news please use our advanced search feature.
OCULAR THERAPEUTIX INC. - More news...
OCULAR THERAPEUTIX INC. - More news...
- Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
- UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
- Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
- Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
- Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
- Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
- Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
- Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
- Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
- Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
- Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
- Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
- Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
- Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
- Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
- Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Ocular Therapeutix™ to Present at the Cowen 42nd Annual Healthcare Conference
- Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update
- Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
- Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
- AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
- Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
- Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
- Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
- Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
- Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
- Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
- Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021